# MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Source: https://onco.cc/trials/nct04110301/  
OnCo record `nct04110301` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Lenalidomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.

## Summary

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) is a phase 1/2 interventional study registered as NCT04110301 by Beijing Mabworks Biotech Co., Ltd., with 53 participants planned, started 2019-11-28 and due to reach its primary completion in 2024-01-09. Interventions recorded: Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide. Conditions listed: Follicular Lymphoma and Marginal Zone Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04110301
- Phase: 1/2
- Setting: A Multi-center, Open Label, Phase 1b/2 Study to Study the Efficacy and Safety of MIL62 Plus Lenalidomide in Subjects With Relapsed/Refractory Follicular Lymphoma or Marginal Zone Lymphoma
- Sponsor: Beijing Mabworks Biotech Co., Ltd.
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT04110301: https://clinicaltrials.gov/study/NCT04110301

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/)
- companies: [Beijing Mabworks Biotech](https://onco.cc/companies/beijing-mabworks-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct04110301.json